Suppr超能文献

药物监管和卫生技术评估决策中的不确定性管理:HTAi-DIA 工作组的指南。

Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group.

机构信息

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.

National Health Care Institute (ZIN), Diemen, The Netherlands.

出版信息

Int J Technol Assess Health Care. 2023 Jun 16;39(1):e40. doi: 10.1017/S0266462323000375.

Abstract

OBJECTIVES

Uncertainty is a fundamental component of decision making regarding access to and pricing and reimbursement of drugs. The context-specific interpretation and mitigation of uncertainty remain major challenges for decision makers. Following the 2021 HTAi Global Policy Forum, a cross-sectoral, interdisciplinary HTAi-DIA Working Group (WG) was initiated to develop guidance to support stakeholder deliberation on the systematic identification and mitigation of uncertainties in the regulatory-HTA interface.

METHODS

Six online discussions among WG members (Dec 2021-Sep 2022) who examined the output of a scoping review, two literature-based case studies and a survey; application of the initial guidance to a real-world case study; and two international conference panel discussions.

RESULTS

The WG identified key concepts, clustered into twelve building blocks that were collectively perceived to define uncertainty: "unavailable," "inaccurate," "conflicting," "not understandable," "random variation," "information," "prediction," "impact," "risk," "relevance," "context," and "judgment." These were converted into a checklist to explain and define whether any issue constitutes a decision-relevant uncertainty. A taxonomy of domains in which uncertainty may exist within the regulatory-HTA interface was developed to facilitate categorization. The real-world case study was used to demonstrate how the guidance may facilitate deliberation between stakeholders and where additional guidance development may be needed.

CONCLUSIONS

The systematic approach taken for the identification of uncertainties in this guidance has the potential to facilitate understanding of uncertainty and its management across different stakeholders involved in drug development and evaluation. This can improve consistency and transparency throughout decision processes. To further support uncertainty management, linkage to suitable mitigation strategies is necessary.

摘要

目的

不确定性是药品准入、定价和报销决策的一个基本组成部分。决策者仍然面临着对不确定性进行具体情境下的解释和缓解的重大挑战。在 2021 年 HTAi 全球政策论坛之后,成立了一个跨部门、跨学科的 HTAi-DIA 工作组(WG),以制定指导意见,支持利益相关者就监管-HTA 界面中不确定性的系统识别和缓解进行审议。

方法

WG 成员进行了六次在线讨论(2021 年 12 月至 2022 年 9 月),他们检查了范围审查、两项基于文献的案例研究和一项调查的结果;将初步指导应用于真实案例研究;并进行了两次国际会议小组讨论。

结果

WG 确定了关键概念,将其聚类为十二个构建块,这些构建块被认为共同定义了不确定性:“不可用”、“不准确”、“冲突”、“不可理解”、“随机变化”、“信息”、“预测”、“影响”、“风险”、“相关性”、“背景”和“判断”。这些被转化为一个清单,以解释和定义任何问题是否构成决策相关的不确定性。还制定了一个监管-HTA 界面中可能存在不确定性的领域分类法,以方便分类。真实案例研究用于演示指导意见如何促进利益相关者之间的审议,以及可能需要进一步制定指导意见的地方。

结论

本指导意见中用于识别不确定性的系统方法有可能促进药品开发和评估涉及的不同利益相关者对不确定性及其管理的理解。这可以提高决策过程的一致性和透明度。为了进一步支持不确定性管理,需要与合适的缓解策略相联系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/333e/11570246/d104f881d181/S0266462323000375_fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验